Related Experiment Video
Updated: Aug 7, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
[Systemic sclerosis--clinical course and treatment possibilities]
Elzbieta Szymańska1, Małgorzata Maj, Lidia Rudnicka
1Klinika Dermatologii CSK MSWiA, 02-507 Warszawa, ul. Wołoska 137. eszymanska@valmed.pl
Przeglad Lekarski
|June 22, 2006
Summary
Systemic sclerosis is an autoimmune disease causing fibrosis in skin and organs. Current therapies target circulation, immune activation, and collagen, as its exact cause remains unknown.
Area of Science:
- Immunology
- Rheumatology
- Pathology
Context:
- Systemic sclerosis (SSc) is a complex autoimmune disease.
- Characterized by widespread fibrosis affecting skin and internal organs (esophagus, heart, lungs, kidneys).
- Three main clinical variants exist: diffuse SSc, limited SSc, and scleroderma sine sclerosis, differing in skin involvement but sharing organ/articular pathology.
Purpose:
- To provide an overview of the clinical course of systemic sclerosis.
- To discuss current therapeutic strategies targeting key pathogenetic factors.
- To highlight emerging therapeutic modalities for SSc management.
Summary:
- Systemic sclerosis involves fibrosis of skin and internal organs, with varied clinical presentations.
- Etiology is unknown, thus no specific cure exists; therapy focuses on managing fibrosis, immune activation, and circulatory issues.
- Treatment aims to influence peripheral circulation, abnormal immune responses, and excessive collagen deposition.
Impact:
- Enhances understanding of systemic sclerosis heterogeneity and shared pathologies.
- Informs clinicians about current management strategies for SSc.
- Highlights the need for novel therapeutics due to the unknown etiology and progressive nature of SSc.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...